PLATFORM
By applying our deep expertise in cancer biology with pioneering high-throughput functional genomic approaches, Tavros has built a next-generation, bi-directional synthetic lethality platform that can precisely and directly identify the paired genetic interactions – with unprecedented speed and scalability – that form the basis for breakthrough targets and first-in-class cancer drugs, new scientific targets and biomarkers.
Cutting-edge functional genomics and computational analysis accelerate the discovery of de-risked, druggable targets with the ultimate goal of improving patient outcomes, minimizing toxicity and quickening development in defined patient subsets.